Week of Feb. 13, 2012: Alexion Completes Acquisition of Enobia Pharma; BMS Completes Acquisition of Inhibitex; and More

The biopharmaceutical company Alexion Pharmaceuticals has completed its $1.1-billion acquisition of 100% of the capital stock of Enobia Pharma, a biopharmaceutical company focused on the development of therapies for treating genetic metabolic disorders. Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and Gray LLP acted as lead legal counsel to Alexion, and Cassels Brock & Blackwell LLP acted as Canadian legal counsel to Alexion. Read More

The CDMO Almac has announced that it is doubling its analytical capacity at its 240,000-ft² North American headquarters in Souderton, Pennsylvania. The facility offers full-service, integrated clinical packaging, drug-supply management, and technology services to pharmaceutical and biotechnology clients. Almac’s additional laboratory investment will include polymorph and salt screening, and solid-form development. The new facility is also equipped with a bathless dissolution apparatus for comparative dissolution studies. Read More

Bosch Packaging Technology has announced plans to acquire the machinery business companies of Eisai. Respective agreements were signed on Feb. 8, 2012. Eisai's machinery business specializes in inspection machinery for the pharmaceutical industry. Bosch Packaging Technology and Eisai have agreed to keep the purchase price confidential. The transaction is subject to compliance with antitrust legislation. Read More

Bristol-Myers Squibb has completed its $2.5-billion acquisition of the clinical-stage biotechnology company Inhibitex. The deal was valued at a purchase price of $26.00 per share. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on Feb. 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures. Read More

Takeda Pharmaceutical has announced the establishment of the Takeda Shanghai Development Center (TDSC) within the Shanghai-based Takeda (China) Holdings (TCH), which is a wholly owned subsidiary of Takeda. TDSC will expand the company’s clinical-development activities within the Asian region, with a focus on China for general medicine. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More